Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Hey

Showing results (221-230 of 228) with videos related to

Pageof 23
Sort By:
You have reached the last page of results.This site can display upto 228 results.
The Journal of Pharmacology and Experimental Therapeutics|June 18, 2002
Pharmacology of N-(3,5-dichloro-1-oxido-4-pyridinyl)-8-methoxy-2-(trifluoromethyl)-5-quinoline carboxamide (SCH 351591), a novel, orally active phosphodiesterase 4 inhibitorM Motasim Billah, Nicola Cooper, Michael Minnicozzi, et al.
European Journal of Pharmacology|September 11, 2002
SCH 206272: a potent, orally active tachykinin NK(1), NK(2), and NK(3) receptor antagonistJohn C Anthes, Richard W Chapman, Christian Richard, et al.
Spine|October 2, 2014
Proximal junctional kyphosis and failure after spinal deformity surgery: a systematic review of the literature as a background to classification developmentDarryl Lau, Aaron J Clark, Justin K Scheer, et al.
Bioorganic & Medicinal Chemistry Letters|October 26, 2005
Novel histamine H3 receptor antagonists based on the 4-[(1H-imidazol-4-yl)methyl]piperidine scaffoldWayne D Vaccaro, Rosy Sher, Michael Berlin, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 15, 2011
Pharmacological characterization of a novel α2C-adrenoceptor agonist N-[3,4-dihydro-4-(1H-imidazol-4-ylmethyl)-2H-1, 4-benzoxazin-6-yl]-N-ethyl-N'-methylurea (compound A)Michel R Corboz, Maria A Rivelli, Kevin D McCormick, et al.
European Journal of Pharmacology|December 17, 2009
Pharmacological profile of the NOP agonist and cough suppressing agent SCH 486757 (8-[Bis(2-Chlorophenyl)Methyl]-3-(2-Pyrimidinyl)-8-Azabicyclo[3.2.1]Octan-3-Ol) in preclinical modelsRobbie L McLeod, Deen B Tulshian, Donald C Bolser, et al.
CNS Drugs|December 1, 2025
Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer's Disease: Synthesis of Evidence from Observational and Interventional TrialsSusan Abushakra, P Murali Doraiswamy, John A Hey, et al.
Bioorganic & Medicinal Chemistry Letters|November 22, 2005
Reduction of CYP450 inhibition in the 4-[(1H-imidazol-4-yl)methyl]piperidine series of histamine H3 receptor antagonistsMichael Berlin, Pauline C Ting, Wayne D Vaccaro, et al.
Pageof 23

Showing results (221-230 of 228) with videos related to

Sort By:
Pageof 23
You have reached the last page of results.This site can display upto 228 results.
The Journal of Pharmacology and Experimental Therapeutics|June 18, 2002
Pharmacology of N-(3,5-dichloro-1-oxido-4-pyridinyl)-8-methoxy-2-(trifluoromethyl)-5-quinoline carboxamide (SCH 351591), a novel, orally active phosphodiesterase 4 inhibitorM Motasim Billah, Nicola Cooper, Michael Minnicozzi, et al.
European Journal of Pharmacology|September 11, 2002
SCH 206272: a potent, orally active tachykinin NK(1), NK(2), and NK(3) receptor antagonistJohn C Anthes, Richard W Chapman, Christian Richard, et al.
Spine|October 2, 2014
Proximal junctional kyphosis and failure after spinal deformity surgery: a systematic review of the literature as a background to classification developmentDarryl Lau, Aaron J Clark, Justin K Scheer, et al.
Bioorganic & Medicinal Chemistry Letters|October 26, 2005
Novel histamine H3 receptor antagonists based on the 4-[(1H-imidazol-4-yl)methyl]piperidine scaffoldWayne D Vaccaro, Rosy Sher, Michael Berlin, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 15, 2011
Pharmacological characterization of a novel α2C-adrenoceptor agonist N-[3,4-dihydro-4-(1H-imidazol-4-ylmethyl)-2H-1, 4-benzoxazin-6-yl]-N-ethyl-N'-methylurea (compound A)Michel R Corboz, Maria A Rivelli, Kevin D McCormick, et al.
European Journal of Pharmacology|December 17, 2009
Pharmacological profile of the NOP agonist and cough suppressing agent SCH 486757 (8-[Bis(2-Chlorophenyl)Methyl]-3-(2-Pyrimidinyl)-8-Azabicyclo[3.2.1]Octan-3-Ol) in preclinical modelsRobbie L McLeod, Deen B Tulshian, Donald C Bolser, et al.
CNS Drugs|December 1, 2025
Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer's Disease: Synthesis of Evidence from Observational and Interventional TrialsSusan Abushakra, P Murali Doraiswamy, John A Hey, et al.
Bioorganic & Medicinal Chemistry Letters|November 22, 2005
Reduction of CYP450 inhibition in the 4-[(1H-imidazol-4-yl)methyl]piperidine series of histamine H3 receptor antagonistsMichael Berlin, Pauline C Ting, Wayne D Vaccaro, et al.
Pageof 23